Manuscripts
Showing 1494 manuscripts.
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial
Citation
Shahin Lockman, Sean Brummel, Lauren Ziemba, Lynda Stranix-Chibanda, Katie McCarthy, Patrick Jean-Philippe, Benjamin Johnston, Chelsea Krotje, Lee Fairlie, Risa Hoffman, Paul E. Sax, Sikhulile Moyo, Nahida Chakhtoura, Jeffrey S. A. Stringer, Gaerolwe Masheto, Violet Korutaro, Haseena Cassim, Blandina Mmbaga, Esau Joao, Sherika Hanley, Lynette Purdue, Lewis Ball Holmes, Jeremiah D. Momper, Roger L. Shapiro, Navdeep Thoofer, James F. Rooney, Lisa Frenkel, K. Rivet Amico, Lameck Chinula, Judith Currier, IMPAACT 2010/VESTED study team and investigators. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2021. 397: 1276-92. PMID: 33812487Journal
Lancet
Study
IMPAACT 2010
Brief Report: Impact of ART on Maternal Health After Cessation of Breastfeeding
Citation
Sean S Brummel, Taha E Taha, Konstantia Angelidou, Friday Saidi, Patience Atuhaire, Dingase Dula, Dhayendre Moodley, ALlen Matubu, Gift Chareka, Neetal Nevrekar, Tichaona Vhembo, Lee Fairlie, Gerhard Theron, Pendo Mlay, Kathleen George, Michael Basar, Nahida Chakhtoura, Renee Browning, Mary Glenn Fowler, Judith S Currier, IMPAACT 1077BF/FF PROMISE Study Team. Brief Report: Impact of ART on Maternal Health After Cessation of Breastfeeding. Journal of Acquired Immune Deficiency Syndromes. 2021. 86: 450-454. PMID: 33273210Journal
Journal of Acquired Immune Deficiency Syndromes
Study
1077BF
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis
Citation
Paul Krogstad, Pearl Samson, Edward P Acosta, Jack Moye, Ellen Townley, Sarah Bradford, Emily Brown, Kayla Denson, Bobbie Graham, Laura Hovind, Thucuma Sise, Hedy Teppler, Sisinyana Ruth Mathiba, Lee Fairlie, Jana L Winckler, Gretchen Slade, Tammy Meyers, International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1101 Team. Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis. Journal of Pediatric Infectious Disease Society. 2021. PMID: 32448902Year
2020
Journal
Journal of Pediatric Infectious Disease Society
Study
P1101
Live-attenuated vaccines prevent respiratory syncytial virus (RSV)-associated illness in young children
Citation
Ruth A. Karron, Jessica E. Atwell, Elizabeth J. MacFarland, Coleen K. Cunningham, Petronella Muresan, Charlotte Perlowski, Jennifer Libous, Stephen A. Spector, Ram Yogev, Mariam Aziz, Suzanne Woods, Kimberli Wanionek, Peter L. Collins, Ursula J. Buchholz. Live-attenuated vaccines prevent respiratory syncytial virus (RSV)-associated illness in young children. American Journal of Respiratory and Critical Care Medicine. 2021. 203: 594-603. PMID: 32871092Journal
American Journal of Respiratory and Critical Care Medicine
Study
P1114, IMPAACT 2000, IMPAACT 2011, IMPAACT 2012, IMPAACT 2013
Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study
Citation
Theodore Ruel, Edmund Capparelli, Camlin Tierney, Bryan Nelson, Anne Coletti, Yvonne Bryson, Mark Cotton, Stephen Spector, Mark Mirochnick, Rebecca LeBlanc, Christina Reding, Bonnie Zimmer, Deborah Persaud, Mutsa Bwakura-Dangarembizi, Kimesh Naidoo, Rohan Hazra, Patrick Jean-Philippe, Ellen Chadwick. Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. Lancet HIV. 2021. 8: e149-e157. PMID: 33242457Year
2022
Journal
Lancet HIV
Study
P1115
Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV: Results from IMPAACT P1026s
Citation
Kristina M Brooks, Jeremiah D Momper, Mauricio Pinilla, Alice M Stek, Emily Barr, Adriana Weinberg, Jaime G Deville, Irma L Febo, Mikhaela Cielo, Kathleen George, Kayla Denson, Kittipong Rungruengthanakit, David E Shapiro, Elizabeth Smith, Nahida Chakhtoura, James F Rooney, Richard Haubrich, Espina Rowena, Edmund V Capparelli, Mark Mirochnick, Brookie M Best, IMPAACT P1026s Protocol Team. Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV: Results from IMPAACT P1026s. AIDS. 2021. 35: 407-417. PMID: 33252495Journal
AIDS
Study
P1026S
Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial
Citation
Lynda Stranix-Chibanda, Camlin Tierney, Dorothy Sebikari , Jim Aizire, Sufia Dadabhai, Admire Zanga, Cynthia Mukwasi-Kahari, Tichaona Vhembo, Avy Violari, Gerard Theron, Dhayandre Moodley , Kathleen George, Bo Fan, Markus J Sommer, Renee Browning, Lynne M Mofenson, John Shepherd, Bryan Nelson, Mary Glenn Fowler, George K Siberry , PROMISE P1084s study team. Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial. PLoS One. 2021. 16: e0246272. PMID: 33544759Journal
PLoS One
Study
P1084s
Impact of tenofovir-containing triple antiretroviral therapy on bone mineral density in breastfeeding women living with HIV enrolled in a randomized clinical trial
Citation
L Stranix-Chibanda, C Teirney, D Sebikari, J Aizire, S Dadabhai, A Zanga, C Mukwasi-Kahari, T Vhembo, A Violari, G Theron, D Moodley, K George, B Fan, M Sommer, R Browning, L Mofenson, J Shepherd, B Nelson, MG Fowler, G Siberry for the PROMISE P1084s Study Team. Impact of tenofovir-containing triple antiretroviral therapy on bone mineral density in breastfeeding women living with HIV enrolled in a randomized clinical trial. PLoS One. 2021. 16: e0246272. PMID: PendingJournal
PLoS One
Study
P1084s
Time to Treatment Disruption in Children on Initial Protease Inhibitor vs. Non-Nucleoside Reverse Transcriptase Inhibitor Regimens
Citation
D Yin, C Ludema, S Cole, C Golin, W Miller, M Warshaw, R McKinney ; on behalf of the PENPACT-1 (PENTA 9 / PACTG 390) Study Team. Time to Treatment Disruption in Children on Initial Protease Inhibitor vs. Non-Nucleoside Reverse Transcriptase Inhibitor Regimens. AIDS. 2020. PMID: 33226999Journal
AIDS
African Multi-Site 2-Year Neuropsychological Study of School-Age Children Perinatally Infected, Exposed, and Unexposed to Human Immunodeficiency Virus
Citation
Michael J. Boivin, Miriam Chernoff, Barbara Laughton, Bonnie Zimmer, Celeste Joyce, Linda Barlow-Mosha, Mutsa Bwakura-Dangarembizi, Tichaona Vhembo, Mmule Ratswana, Lee Fairlie, Portia Kamthunzi, Katie McCarthy, Itziar Familiar-Lopez, Patrick Jean-Philippe, Joan Coetzee, Nasreen Abrahams, Hermien Gous, Avy Violari, Mark F. Cotton, Paul Palumbo, IMPAACT P1104s Study Team. African Multi-Site 2-Year Neuropsychological Study of School-Age Children Perinatally Infected, Exposed, and Unexposed to Human Immunodeficiency Virus. Clinical Infectious Diseases. 2020. 71: e105-e114. PMID: 31848582Journal
Clinical Infectious Diseases
Study
P1104s